Compare STAA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAA | FTRE |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1995 | 2023 |
| Metric | STAA | FTRE |
|---|---|---|
| Price | $23.72 | $19.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $22.81 | $14.06 |
| AVG Volume (30 Days) | 958.8K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | $239,442,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $8.41 | $3.09 |
| P/E Ratio | $243.60 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $15.59 | $5.82 |
| 52 Week High | $35.87 | $21.39 |
| Indicator | STAA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 58.79 |
| Support Level | $23.71 | $15.69 |
| Resistance Level | $24.26 | N/A |
| Average True Range (ATR) | 1.52 | 1.07 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 34.23 | 46.27 |
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.